Discovery of a novel hybrid coumarin-hydroxamate conjugate targeting the HDAC1-Sp1-FOSL2 signaling axis for breast cancer therapy

Discovery of a novel hybrid coumarin-hydroxamate conjugate targeting the HDAC1-Sp1-FOSL2 signaling axis for breast cancer therapy

Abstract Background Breast cancer is one of the most lethal cancers in women. Despite significant advances in the diagnosis and treatment of breast cancer, many patients still succumb to this disease, and thus, novel effective treatments are urgently needed. Natural product coumarin has been broadly...

Descripció completa

Dades bibliogràfiques
Autors principals:	Sujie Zhu, Wenjing Zhu, Kaihua Zhao, Jie Yu, Wenxia Lu, Rui Zhou, Shule Fan, Weikaixin Kong, Feifei Yang, Peipei Shan
Format:	Article
Idioma:	English
Publicat:	BMC 2024-07-01
Col·lecció:	Cell Communication and Signaling
Matèries:	Breast cancer Metastasis Tumor growth Histone deacetylases inhibitor Coumarins FOSL2
Accés en línia:	https://doi.org/10.1186/s12964-024-01733-4

Ítems similars

The Role of HDACs as Leukemia Therapy Targets using HDI
per: Ahmad Ahmadzadeh, et al.
Publicat: (2016-02-01)

KLF14 inhibits tumor progression via FOSL1 in glioma
per: Xiaohua Wang, et al.
Publicat: (2025-03-01)

Design, Synthesis and Biological Evaluation of Novel Coumarin-Based Hydroxamate Derivatives as Histone Deacetylase (Hdac) Inhibitors with Antitumor Activities
per: Feifei Yang, et al.
Publicat: (2019-07-01)

Influence of FOSL1 Inhibition on Vascular Calcification and ROS Generation through Ferroptosis via P53-SLC7A11 Axis
per: Sisi Shao, et al.
Publicat: (2023-02-01)

Small Molecules Targeting HATs, HDACs, and BRDs in Cancer Therapy
per: Donglu Wu, et al.
Publicat: (2020-11-01)

NF1 regulates mesenchymal glioblastoma plasticity and aggressiveness through the AP-1 transcription factor FOSL1
per: Carolina Marques, et al.
Publicat: (2021-08-01)

All for one and FOSL1 for all: FOSL1 at the crossroads of lung and pancreatic cancer driven by mutant KRAS
per: Adrian Vallejo, et al.
Publicat: (2017-05-01)

FOSL1 promotes tumor growth and invasion in ameloblastoma
per: Gan Xiong, et al.
Publicat: (2022-09-01)

Targeted intervention of tumor microenvironment with HDAC inhibitors and their combination therapy strategies
per: Wanli Zhang, et al.
Publicat: (2025-02-01)

Non-Hydroxamate Zinc-Binding Groups as Warheads for Histone Deacetylases
per: Anton Frühauf, et al.
Publicat: (2021-08-01)

PMAIP1 regulates the progression of follicular thyroid carcinoma through the Wnt3/FOSL1 pathway
per: Haobo Wang, et al.
Publicat: (2025-01-01)

HAT- and HDAC-Targeted Protein Acetylation in the Occurrence and Treatment of Epilepsy
per: Jie Wang, et al.
Publicat: (2022-12-01)

Super-enhancer-associated SNHG15 cooperating with FOSL1 contributes to bladder cancer progression through the WNT pathway
per: Mingyue Tan, et al.
Publicat: (2023-11-01)

The Emerging Role of HDACs: Pathology and Therapeutic Targets in Diabetes Mellitus
per: Saikat Dewanjee, et al.
Publicat: (2021-05-01)

FOSL1 is a key regulator of a super-enhancer driving TCOF1 expression in triple-negative breast cancer
per: Qingling He, et al.
Publicat: (2024-11-01)

FOSL2 activates TGF‐β1‐mediated GLUT1/mTOR signaling to promote diabetic kidney disease
per: Xuelin He, et al.
Publicat: (2025-02-01)

The Importance of the “Time Factor” for the Evaluation of Inhibition Mechanisms: The Case of Selected HDAC6 Inhibitors
per: Edoardo Cellupica, et al.
Publicat: (2023-07-01)

Metabolism, HDACs, and HDAC Inhibitors: A Systems Biology Perspective
per: Jacob King, et al.
Publicat: (2021-11-01)

Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors
per: Elizabeth A. Thomas
Publicat: (2014-05-01)

HDAC1-mediated deacetylation of HIF1α prevents atherosclerosis progression by promoting miR-224-3p-mediated inhibition of FOSL2
per: Hao Wang, et al.
Publicat: (2021-03-01)

FOSL1 drives the malignant progression of pancreatic cancer cells by regulating cell stemness, metastasis and multidrug efflux system
per: Xiaolong Liu, et al.
Publicat: (2025-03-01)

MiR-33a targets FOSL1 and EN2 as a clinical prognostic marker for sarcopenia by glioma
per: Wei Wang, et al.
Publicat: (2022-08-01)

Design of Fluorescent Coumarin-Hydroxamic Acid Derivatives as Inhibitors of HDACs: Synthesis, Anti-Proliferative Evaluation and Docking Studies
per: Santiago García, et al.
Publicat: (2020-11-01)

Current HDAC Inhibitors in Clinical Trials
per: Elisabetta Di Bello, et al.
Publicat: (2022-05-01)

Development of Coumarin-Based Hydroxamates as Histone Deacetylase Inhibitors with Antitumor Activities
per: Na Zhao, et al.
Publicat: (2020-02-01)

Synthesis, Antiplasmodial, and Antileukemia Activity of Dihydroartemisinin–HDAC Inhibitor Hybrids as Multitarget Drugs
per: Lukas von Bredow, et al.
Publicat: (2022-03-01)

CircCRIM1 promotes nasopharyngeal carcinoma progression via the miR-34c-5p/FOSL1 axis
per: Weifeng He, et al.
Publicat: (2022-04-01)

Exploration of quinazoline-tethered hydroxamic acid derivatives as HDAC inhibitors for anticancer activity: Design, synthesis, molecular docking, and biological evaluation
per: Shweta Mishra, et al.
Publicat: (2024-01-01)

Molecular Docking Simulations on Histone Deacetylases (HDAC)-1 and -2 to Investigate the Flavone Binding
per: Bernardina Scafuri, et al.
Publicat: (2020-12-01)

Optimization of Resveratrol Used as a Scaffold to Design Histone Deacetylase (HDAC-1 and HDAC-2) Inhibitors
per: Beatriz Silva Urias, et al.
Publicat: (2022-10-01)

Hydroxamic Acid as a Potent Metal-Binding Group for Inhibiting Tyrosinase
per: Joonhyeok Choi, et al.
Publicat: (2022-01-01)

Overexpression of FRA1 (<i>FOSL1</i>) Leads to Global Transcriptional Perturbations, Reduced Cellular Adhesion and Altered Cell Cycle Progression
per: Wuroud Al-khayyat, et al.
Publicat: (2023-09-01)

Introducing HDAC-Targeting Radiopharmaceuticals for Glioblastoma Imaging and Therapy
per: Liesbeth Everix, et al.
Publicat: (2023-02-01)

HDAC6 Enhances Endoglin Expression through Deacetylation of Transcription Factor SP1, Potentiating BMP9-Induced Angiogenesis
per: Chen Sun, et al.
Publicat: (2024-03-01)

Multimodal nanoparticle‐containing modified suberoylanilide hydroxamic acid polymer conjugates to mitigate immune dysfunction in severe inflammation
per: Nhu Truong, et al.
Publicat: (2024-01-01)

Design, synthesis, and biological evaluation of substituted benzyl-triazolopyridine derivatives as non-hydroxamate based HDAC8 inhibitors
per: N.V.M. Rao Bandaru, et al.
Publicat: (2025-04-01)

The replication timing program in the hands of two HDACs
per: Kazumasa Yoshida, et al.
Publicat: (2014-07-01)

Emerging role of HDAC11 in skeletal muscle biology
per: Jihong Chen, et al.
Publicat: (2024-05-01)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
per: Masumeh Sanaei, et al.
Publicat: (2019-01-01)

Synovial Fluid Derived from Human Knee Osteoarthritis Increases the Viability of Human Adipose-Derived Stem Cells through Upregulation of FOSL1
per: Hironori Kitajima, et al.
Publicat: (2023-01-01)